BioWorld

Jan. 14, 2009

ZymoGenetics Soars 26% on $1.1B HCV Drug Deal with BMS

ZymoGenetics Inc.'s stock leaped 26 percent Tuesday on the news that it signed a deal potentially worth more than $1.1 billion with pharma giant Bristol-Myers Squibb Co. to develop and commercialize the Seattle-based biotech's early-stage hepatitis C drug. (BioWorld Today) Read More

Medicines to Acquire Targanta; Deal Staged from $42M to $138M

Innate, Adaptive Immune System: More in Common than Thought

Apitope, Merck Collaborating in $203M Deal for MS Drug

Antisoma's ASA404 Starts 2nd Phase III Study in Lung Cancer

Dimon Argues for Some Form of Universal Health Care in U.S.

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa

BioWorld Science

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...

TL1A is overexpressed in hidradenitis suppurativa

BioWorld Science

Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...

Illustration of head with maze that is missing parts

Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke

BioWorld Science

Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...

VST Bio’s VB-001 is neuroprotector after stroke

BioWorld Science

At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...